Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (522)	7/27/2019 6:35:44 PM
From: BulbaMan	Read Replies (1) \| Respond to of 684

For sure, the CEO’s reputation for deal-making and self-dealing would be a factor. And I assume you agree that not all biotechs with failed drugs also had lousy management. In any case, what I was wondering was whether age was a factor as well. Apparently, you think not. Oh well, another brilliant idea that may not be so brilliant after all. ;~) (The age idea was partly inspired by the IMDZ buyout by Merck at a huge premium. Carlos Paya, IMDZ CEO, was 60 when the buyout was announced and the median age of the IMDZ BOD was 67.) Peace & good health, Bulba

To: rkrw who wrote (522)	7/30/2019 9:06:19 AM
From: Lance Bredvold	Read Replies (1) \| Respond to of 684

CABG but it's a while ago. And heart valve replacement rather than drug.

To: rkrw who wrote (522)	8/5/2019 4:35:52 PM
From: rkrw	Read Replies (2) \| Respond to of 684

I stand corrected, came across this one that traded their cash for equivalent shares in another company. *Acquisition Expected to be Completed by Mid-Year 2019* VANCOUVER and HOUSTON, May 16, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ: EPIX; TSX-V: EPI) announced today that it has entered into a definitive agreement with Realm Therapeutics plc ("Realm") (NASDAQ: RLM) setting forth the terms of an acquisition ("Acquisition") whereby ESSA will acquire all of the issued and outstanding shares of Realm in an all-stock transaction. The Acquisition, subject inter alia to Realm Shareholder approval, is intended to be implemented by means of a United Kingdom ("UK") Court-sanctioned scheme of arrangement under Part 26 of the UK Companies Act 2006 and is expected to be completed by mid-year 2019. Upon the closing of the Acquisition, the Company will continue to operate as ESSA Pharma Inc., trade on the Nasdaq Capital Market and TSX-V Market and operate in the United States as ESSA Pharmaceuticals Corp., a Houston, TX-registered wholly-owned subsidiary. The Company will focus on advancing ESSA's pipeline of novel potential treatments for prostate and other cancers. The terms of the Acquisition value Realm's issued and outstanding shares at approximately USD $21.5 million, which represents a 5% premium over Realm's estimated net cash amount of USD $20.5 million at the closing of the Acquisition.